<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy : CII</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998677</article-id><article-id pub-id-type="pmc">PMC11861821</article-id>
<article-id pub-id-type="publisher-id">3964</article-id><article-id pub-id-type="doi">10.1007/s00262-025-03964-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sirni&#x000f6;</surname><given-names>P&#x000e4;ivi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elomaa</surname><given-names>Hanna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tuomisto</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>&#x000c4;ij&#x000e4;l&#x000e4;</surname><given-names>Ville K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Karjalainen</surname><given-names>Henna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kastinen</surname><given-names>Meeri</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tapiainen</surname><given-names>Vilja V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sirki&#x000e4;</surname><given-names>Onni</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ahtiainen</surname><given-names>Maarit</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Helminen</surname><given-names>Olli</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wirta</surname><given-names>Erkki-Ville</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Rintala</surname><given-names>Jukka</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meril&#x000e4;inen</surname><given-names>Sanna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Saarnio</surname><given-names>Juha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rautio</surname><given-names>Tero</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sepp&#x000e4;l&#x000e4;</surname><given-names>Toni T.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>B&#x000f6;hm</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mecklin</surname><given-names>Jukka-Pekka</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000e4;kinen</surname><given-names>Markus J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8683-2996</contrib-id><name><surname>V&#x000e4;yrynen</surname><given-names>Juha P.</given-names></name><address><email>juha.vayrynen@oulu.fi</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/045ney286</institution-id><institution-id institution-id-type="GRID">grid.412326.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 4685 4917</institution-id><institution>Translational Medicine Research Unit, Medical Research Center Oulu, </institution><institution>Oulu University Hospital, and University of Oulu, </institution></institution-wrap>Aapistie 5A, 90220 Oulu, Finland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3dz165</institution-id><institution-id institution-id-type="GRID">grid.9681.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 1013 7965</institution-id><institution>Department of Biological and Environmental Science, </institution><institution>University of Jyv&#x000e4;skyl&#x000e4;, </institution></institution-wrap>Jyv&#x000e4;skyl&#x000e4;, Finland </aff><aff id="Aff3"><label>3</label>Department of Education and Research, Well Being Services County of Central Finland, Jyv&#x000e4;skyl&#x000e4;, Finland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.513298.4</institution-id><institution>Department of Pathology, </institution><institution>Hospital Nova of Central Finland, Well Being Services County of Central Finland, </institution></institution-wrap>Jyv&#x000e4;skyl&#x000e4;, Finland </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cyydd11</institution-id><institution-id institution-id-type="GRID">grid.9668.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 2490</institution-id><institution>Department of Environmental and Biological Sciences, </institution><institution>University of Eastern Finland, </institution></institution-wrap>Kuopio, Finland </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02hvt5f17</institution-id><institution-id institution-id-type="GRID">grid.412330.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0628 2985</institution-id><institution>Department of Gastroenterology and Alimentary Tract Surgery, </institution><institution>Tampere University Hospital, </institution></institution-wrap>Tampere, Finland </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02hvt5f17</institution-id><institution-id institution-id-type="GRID">grid.412330.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0628 2985</institution-id><institution>Faculty of Medicine and Health Technology, </institution><institution>Tampere University and Tays Cancer Centre, Tampere University Hospital, </institution></institution-wrap>Tampere, Finland </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040af2s02</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution>Department of Gastrointestinal Surgery, </institution><institution>Helsinki University Central Hospital, University of Helsinki, </institution></institution-wrap>Helsinki, Finland </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040af2s02</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution>Applied Tumor Genomics, Research Program Unit, </institution><institution>University of Helsinki, </institution></institution-wrap>Helsinki, Finland </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3dz165</institution-id><institution-id institution-id-type="GRID">grid.9681.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 1013 7965</institution-id><institution>Faculty of Sport and Health Sciences, </institution><institution>University of Jyv&#x000e4;skyl&#x000e4;, </institution></institution-wrap>Jyv&#x000e4;skyl&#x000e4;, Finland </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>74</volume><issue>4</issue><elocation-id>111</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Caudal-type homeobox 2 (CDX2) and special AT-rich sequence-binding protein 2 (SATB2) are transcription factors playing important roles in intestinal homeostasis and participating in the regulation of intestinal inflammation. In colorectal cancer (CRC), reduced expression levels of CDX2 and SATB2 have been associated with poor differentiation and worse survival. However, their prognostic significance still needs further clarification, and the associations between CDX2 and SATB2 and immune cell infiltration into the CRC microenvironment are largely unknown.</p></sec><sec><title>Methods</title><p id="Par2">We analyzed CDX2 and SATB2 expression in two large cohorts of stages I&#x02013;IV CRC patients (<italic>N</italic>&#x000a0;=&#x000a0;2302) and analyzed their associations with clinicopathologic parameters, the density of local immune cells (determined with three multiplex immunohistochemistry panels and conventional immunohistochemistry), and survival.</p></sec><sec><title>Results</title><p id="Par3">In mismatch repair-proficient tumors, reduced CDX2 and SATB2 expression were associated with higher densities of immature monocytic cells, macrophages, and M2-like macrophages. Low expression of CDX2 was associated with shorter cancer-specific survival independent of conventional prognostic parameters in both cohorts. In the larger cohort, adjusted hazard ratio (HR) for negative (vs. high) CDX2 expression was 3.62 (95% CI 2.08&#x02013;6.31, <italic>p</italic><sub>trend</sub>&#x000a0;&#x0003c;&#x000a0;0.0001), and adjusted HR for negative (vs. high) SATB2 level was 1.61 (95% CI 0.97&#x02013;2.67, <italic>p</italic><sub>trend&#x000a0;</sub>=&#x000a0;0.002).</p></sec><sec><title>Conclusion</title><p id="Par4">This study indicates that reduced CDX2 and SATB2 expression levels are associated with myeloid cell infiltration in the CRC microenvironment and represent markers for poor outcome. These findings highlight the potential of CDX2 and SATB2 as biomarkers for classifying CRC patients and support their role in regulating the tumor microenvironment.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00262-025-03964-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal cancer</kwd><kwd>CDX2</kwd><kwd>SATB2</kwd><kwd>Immune cells</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Finnish State Research Funding</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010711</institution-id><institution>Sy&#x000f6;p&#x000e4;s&#x000e4;&#x000e4;ti&#x000f6;</institution></institution-wrap></funding-source><award-id>59-5619</award-id><principal-award-recipient><name><surname>V&#x000e4;yrynen</surname><given-names>Juha P.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004756</institution-id><institution>Emil Aaltosen S&#x000e4;&#x000e4;ti&#x000f6;</institution></institution-wrap></funding-source><award-id>220257P</award-id><principal-award-recipient><name><surname>V&#x000e4;yrynen</surname><given-names>Juha P.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008723</institution-id><institution>Suomen L&#x000e4;&#x000e4;ketieteen S&#x000e4;&#x000e4;ti&#x000f6;</institution></institution-wrap></funding-source><award-id>6021</award-id><principal-award-recipient><name><surname>V&#x000e4;yrynen</surname><given-names>Juha P.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006306</institution-id><institution>Sigrid Jus&#x000e9;liuksen S&#x000e4;&#x000e4;ti&#x000f6;</institution></institution-wrap></funding-source><award-id>230229</award-id><principal-award-recipient><name><surname>V&#x000e4;yrynen</surname><given-names>Juha P.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Oulu (including Oulu University Hospital)</institution></funding-source></award-group><open-access><p>Open Access funding provided by University of Oulu (including Oulu University Hospital).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par19">Caudal-type homeobox 2 (CDX2) and special AT-rich sequence-binding protein 2 (SATB2) are transcription factors regulating gene expression in the intestine. CDX2 is normally expressed within the nuclei of intestinal epithelial cells and plays a crucial role in the development and maintenance of the intestinal epithelium [<xref ref-type="bibr" rid="CR1">1</xref>]. SATB2 is highly expressed in the lower gastrointestinal epithelium and specific neurons in brain and is particularly important in the development of neural, craniofacial, and osteoblastic structures [<xref ref-type="bibr" rid="CR2">2</xref>]. In the colon, SATB2 is required for maintaining colonic identity of stem cells and differentiated cells [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par20">CDX2 and SATB2 have been linked to colorectal cancer (CRC) progression. They both are used as immunohistochemical markers for colorectal origin in tumors and are advantageous in distinguishing metastatic colorectal adenocarcinoma from other adenocarcinomas [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. However, their expression is reduced or lost in a subset of CRCs, most often poorly differentiated CRCs [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Reduced expression has been found to be associated with worse survival and several unfavorable prognostic factors, including advanced stage, higher tumor grade, and <italic>BRAF</italic> mutation [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Decreased CDX2 and SATB2 expression is also associated with mismatch repair (MMR) protein deficiency in CRC [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par21">High immune cell infiltration generally predicts better outcome in CRC [<xref ref-type="bibr" rid="CR17">17</xref>]. The immune cell infiltrate can be quantified using the Immunoscore, a scoring system based on the density of CD3<sup>+</sup> and CD8<sup>+</sup> cell populations both at the tumor center and at the invasive margin [<xref ref-type="bibr" rid="CR18">18</xref>]. A high Immunoscore predicts longer survival, and the prognostic power of the Immunoscore has been validated by a worldwide consortium [<xref ref-type="bibr" rid="CR19">19</xref>]. In recent years, CDX2 and SATB2 have been increasingly linked to intestinal inflammation. CDX2 has been shown to regulate inflammasome activity through expression of the NLRP3 suppressor TRIM31 [<xref ref-type="bibr" rid="CR20">20</xref>]. In the mouse colon epithelium, loss of Cdx function leads to elevated infiltration of macrophages and expression of proinflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Also, the expression of CDX2 and SATB2 has been shown to be decreased in the epithelium of patients with inflammatory bowel disease, and Satb2-deficient mice are more prone to the development of colitis and colitis-associated cancer compared with control mice [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. However, the potential role of CDX2 and SATB2 in the inflammatory response in human CRC is largely unknown.</p><p id="Par22">The primary aim of this study was to evaluate the associations between CDX2 and SATB2 expression and tumor-infiltrating immune cells in CRC. The secondary aim was to confirm the prognostic value of CDX2 and SATB2 in CRC.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p id="Par23">This study was based on two independent cohorts. Cohort 1 was retrospectively collected in Central Finland Central Hospital in Jyv&#x000e4;skyl&#x000e4;. It included 1343 patients who had undergone tumor resection during 2000&#x02013;2015 [<xref ref-type="bibr" rid="CR26">26</xref>]. Cohort 2 was prospectively collected of 1011 newly diagnosed CRC patients operated in the Oulu University Hospital between 2006 and 2020, who had signed an informed consent to participate and were eligible to the study [<xref ref-type="bibr" rid="CR27">27</xref>]. Patients who had received preoperative radiotherapy or chemoradiotherapy (Cohort 1: <italic>N</italic>&#x000a0;=&#x000a0;243; Cohort 2: <italic>N</italic>&#x000a0;=&#x000a0;235) were excluded from immune cell analyses, and patients who died within 30&#x000a0;days of initial surgery (Cohort 1: <italic>N</italic>&#x000a0;=&#x000a0;40; Cohort 2: <italic>N</italic>&#x000a0;=&#x000a0;5) were excluded from survival analysis.</p></sec><sec id="Sec4"><title>Immunohistochemistry and image analysis</title><p id="Par24">Immunohistochemistry was conducted on tissue microarrays (TMAs) that were constructed from formalin-fixed paraffin-embedded tissue samples and were designed to contain four cores (diameter 1 mm) per case, two from the center of the tumor (CT) and two from the invasive margin (IM) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. MMR enzyme screening status for MLH1, MSH2, MSH6, and PMS2, and <italic>BRAF</italic> V600E mutation status had been previously examined with immunohistochemistry [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The immune cell analyses for Cohort 1 were based on multiplex immunohistochemistry and quantitative image analyses. The multiplex immunohistochemistry staining protocol, reagents, and the primary antibodies along with their dilutions and epitope retrieval conditions are demonstrated in Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>. Analyses of tumor-infiltrating immune cells were conducted with supervised machine learning approaches built-in QuPath [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The cell types investigated in this study included CD3<sup>+</sup> T cells, CD20<sup>+</sup>CD79A<sup>+</sup> B cells, CD20<sup>-</sup>CD79A<sup>+</sup> plasma cells, M1-like and M2-like macrophages, CD14<sup>+</sup>HLA-DR<sup>+</sup> mature monocytic cells, CD14<sup>+</sup>HLA-DR<sup>-</sup> immature monocytic cells, CD66B<sup>+</sup> granulocytes, and tryptase<sup>+</sup> mast cells. Macrophages were categorized according to their polarization by calculating a polarization index for each macrophage [<xref ref-type="bibr" rid="CR28">28</xref>]. Immune cell score was calculated according to the principles of Immunoscore&#x000ae; [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par25">An automated immunostainer (BOND-III, Leica Biosystems, Germany) and the BOND Refine detection kit (Leica Biosystems) were used for the immunohistochemical staining of CDX2 (Epredia RM-2116, clone EPR2764Y, 1:500) and SATB2 (Cell Marque 384R-16, clone EP281, 1:80). BOND Epitope Retrieval Solution 2 (Leica Biosystems, AR9640) was used in the pretreatment (100&#x000a0;&#x000b0;C, 30 min). The slides were scanned with NanoZoomer XR (Hamamatsu Photonics, Hamamatsu City, Japan) scanner using 20&#x000d7; objective magnification. Scanned images were analyzed with QuPath (version 0.4.4). In QuPath, cell detection function was used to detect cells, add intensity features function was used to calculate Haralick&#x02019;s texture features, and add smoothed features function was used to calculate smoothed features (within 20&#x000a0;&#x000b5;m). An object classifier was then trained to recognize tumor and stromal cells. The intensity of DAB (3,3&#x02019;-Diaminobenzidine) chromogen was measured for each tumor cell with QuPath, and the cell data were processed using RStudio and R statistical programming (version 4.3.1, R core Team). For each cell, DAB intensity was classified into four categories. For CDX2, DAB&#x02009;&#x000a0;&#x0003c;&#x000a0;&#x02009;0.25 intensity units indicated negative, DAB 0.25&#x02013;0.55 weakly positive, DAB 0.55&#x02013;0.85 moderately positive, and DAB&#x000a0;&#x02009;&#x0003e;&#x000a0;&#x02009;0.85 strongly positive staining. For SATB2, DAB&#x000a0;&#x02009;&#x0003c;&#x02009;&#x000a0;0.2 intensity units indicated negative, DAB 0.2&#x02013;0.4 weakly positive, DAB 0.4&#x02013;0.6 moderately positive, and DAB&#x000a0;&#x02009;&#x0003e;&#x02009;&#x000a0;0.6 strongly positive staining. The mean histoscore for each core was calculated using the formula: 1&#x000a0;&#x000d7;&#x000a0;percentage of tumor cells showing weak staining + 2&#x000a0;&#x000d7;&#x000a0;percentage of tumor cells showing moderate staining + 3&#x000a0;&#x000d7;&#x000a0;percentage of tumors cells showing intensive staining. For each tumor, a single histoscore was calculated as the average of histoscores from all individual cores, and tumors were categorized into negative (histoscore&#x000a0;&#x0003c;&#x000a0;5), low (histoscore&#x000a0;&#x02265;&#x000a0;5 and &#x0003c;&#x000a0;100), and high expression (histoscore&#x000a0;&#x02265;&#x000a0;100) [<xref ref-type="bibr" rid="CR30">30</xref>]. Examples of TMA cores with cell classification and different CDX2 and SATB2 expression groups are presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>CDX2 and SATB2 immunohistochemistry. <bold>A</bold> Cell detection and classification of one TMA core using QuPath. In the image analysis result image, red color represents cancer cells and yellow other cells. <bold>B</bold> Examples of TMA cores with high, low, and negative CDX2 and SATB2 expression</p></caption><graphic xlink:href="262_2025_3964_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Statistical analyses</title><p id="Par26">The statistical analyses were conducted using IBM SPSS Statistics for Windows version 29.0.0.0 (IBM Corporation, Armonk, NY, USA). Chi-square test was used to characterize the relationship between categorical variables. Correlations between two continuous variables were determined using the Spearman&#x02019;s rank correlation test. The 2D visualization was created with Cytoscape software platform [<xref ref-type="bibr" rid="CR31">31</xref>], utilizing the Prefuse force directed algorithm weighted by the statistical significances of the correlations between individual variables. Survival rates were visualized by the Kaplan&#x02013;Meier method, and the statistical significance was tested with the log-rank test. Cancer-specific survival (CSS; time from operation to CRC death) was the primary endpoint. Hazard ratios (HRs) with 95% confidence interval (CI) were calculated using Cox proportional hazard models. Multivariable Cox regression models included the following pre-determined covariates: age (&#x0003c;&#x000a0;65, 65&#x02013;75, and &#x0003e;&#x000a0;75), sex (male and female), stage (I, II, III, and IV), MMR enzyme status (proficient and deficient), <italic>BRAF</italic> V600E mutation status (wild-type and mutant), tumor location (proximal colon, distal colon, and rectum), year of operation (Cohort 1: 2000&#x02013;2005, 2006&#x02013;2010, and 2011&#x02013;2015; Cohort 2: 2006-2010, 2011&#x02013;2015, and 2016-2020), lymphatic or venous invasion (no and yes), grade (low-grade and high-grade), and preoperative radiotherapy or chemoradiotherapy (no and yes). A two-tailed <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01 was considered statistically significant.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Distribution of CDX2 and SATB2 staining and association with clinicopathological characteristics</title><p id="Par27">The expression of CDX2 and SATB2 was detected in variable proportions of tumor cell nuclei, while stromal cells were negative for both. The associations of CDX2 and SATB2 histoscore with tumor and patient characteristics are shown in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>. CDX2 and SATB2 expression could be evaluated from 1329 patients in Cohort 1 and 973 patients in Cohort 2. Of them, 32 (2%) in Cohort 1 and 22 (2%) in Cohort 2 had loss of CDX2 expression, 95 (7%) and 50 (5%) low CDX2 expression and 1202 (90%) and 901 (93%) high CDX2 expression. SATB2 expression was negative in 55 (4%) tumors in Cohort 1 and 120 (12%) tumors in Cohort 2, low in 265 (20%) and 206 (21%) and high in 1009 (76%) and 647 (67%) tumors. In both cohorts, lower CDX2 and SATB2 expression levels were associated with proximal tumor location, high tumor grade, MMR deficiency, and <italic>BRAF</italic> V600E mutation (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 for all). CDX2 and SATB2 expression groups were associated with one another (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). In Cohort 1, low expression of CDX2 and SATB2 was also related to advanced stage (<italic>p</italic>&#x000a0;=&#x000a0;0.004 and <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, respectively) and lymphovascular invasion (<italic>p</italic>&#x000a0;=&#x000a0;0.008 and <italic>p</italic>&#x000a0;=&#x000a0;0.002, respectively).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Associations between CDX2 expression and clinicopathological parameters in colorectal cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristic</th><th align="left" colspan="5">Cohort 1</th><th align="left" colspan="5">Cohort 2</th></tr><tr><th align="left">Total N</th><th align="left">High</th><th align="left">Low</th><th align="left">Negative</th><th align="left"><italic>p</italic></th><th align="left">Total N</th><th align="left">High</th><th align="left">Low</th><th align="left">Negative</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left">All cases</td><td align="left">1329 (100%)</td><td align="left">1202 (90%)</td><td align="left">95 (7%)</td><td align="left">32 (2%)</td><td align="left"/><td align="left">973 (100%)</td><td align="left">901 (93%)</td><td align="left">50 (5%)</td><td align="left">22 (2%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>Sex</italic></td></tr><tr><td align="left">Female</td><td align="left">618 (47%)</td><td align="left">548 (46%)</td><td align="left">49 (52%)</td><td align="left">21 (66%)</td><td align="left">0.048</td><td align="left">425 (44%)</td><td align="left">382 (58%)</td><td align="left">29 (58%)</td><td align="left">14 (64%)</td><td align="left">0.016</td></tr><tr><td align="left">Male</td><td align="left">711 (54%)</td><td align="left">654 (54%)</td><td align="left">46 (48%)</td><td align="left">11 (34%)</td><td align="left"/><td align="left">548 (56%)</td><td align="left">519 (42%)</td><td align="left">21 (42%)</td><td align="left">8 (36%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>Age (years)</italic></td></tr><tr><td align="left">&#x0003c;65</td><td align="left">395 (30%)</td><td align="left">364 (30%)</td><td align="left">22 (23%)</td><td align="left">9 (28%)</td><td align="left">0.243</td><td align="left">330 (34%)</td><td align="left">303 (34%)</td><td align="left">20 (40%)</td><td align="left">7 (32%)</td><td align="left">0.769</td></tr><tr><td align="left">65&#x02013;75</td><td align="left">454 (34%)</td><td align="left">415 (35%)</td><td align="left">31 (33%)</td><td align="left">8 (25%)</td><td align="left"/><td align="left">356 (37%)</td><td align="left">334 (37%)</td><td align="left">14 (28%)</td><td align="left">8 (36%)</td><td align="left"/></tr><tr><td align="left">&#x0003e;75</td><td align="left">480 (36%)</td><td align="left">423 (35%)</td><td align="left">42 (44%)</td><td align="left">15 (47%)</td><td align="left"/><td align="left">287 (29%)</td><td align="left">264 (29%)</td><td align="left">16 (32%)</td><td align="left">7 (32%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>Tumor location</italic></td></tr><tr><td align="left">Proximal colon</td><td align="left">532 (40%)</td><td align="left">445 (37%)</td><td align="left">63 (66%)</td><td align="left">24 (75%)</td><td align="left">&#x0003c;0.001</td><td align="left">321 (33%)</td><td align="left">279 (31%)</td><td align="left">26 (52%)</td><td align="left">16 (73%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Distal colon</td><td align="left">399 (30%)</td><td align="left">387 (32%)</td><td align="left">8 (8%)</td><td align="left">4 (13%)</td><td align="left"/><td align="left">205 (21%)</td><td align="left">200 (22%)</td><td align="left">3 (6%)</td><td align="left">2 (9%)</td><td align="left"/></tr><tr><td align="left">Rectum</td><td align="left">398 (30%)</td><td align="left">370 (31%)</td><td align="left">24 (25%)</td><td align="left">4 (13%)</td><td align="left"/><td align="left">447 (46%)</td><td align="left">422 (47%)</td><td align="left">21 (42%)</td><td align="left">4 (18%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>Preoperative RT/CRT</italic></td></tr><tr><td align="left"><p>No</p><p>Yes</p></td><td align="left"><p>1091 (82%)</p><p>239 (18%)</p></td><td align="left"><p>984 (82%)</p><p>218 (18%)</p></td><td align="left"><p>77 (81%)</p><p>18 (19%)</p></td><td align="left"><p>30 (91%)</p><p>3 (9%)</p></td><td align="left">0.397</td><td align="left"><p>759 (78%)</p><p>214 (22%)</p></td><td align="left"><p>701 (78%)</p><p>200 (22%)</p></td><td align="left"><p>39 (78%)</p><p>11 (22%)</p></td><td align="left"><p>19 (86%)</p><p>3 (14%)</p></td><td align="left">0.632</td></tr><tr><td align="left" colspan="11"><italic>AJCC disease stage</italic></td></tr><tr><td align="left">I</td><td align="left">246 (19%)</td><td align="left">238 (20%)</td><td align="left">7 (7%)</td><td align="left">0 (0.0%)</td><td align="left">0.004</td><td align="left">213 (22%)</td><td align="left">202 (22%)</td><td align="left">8 (16%)</td><td align="left">3 (14%)</td><td align="left">0.124</td></tr><tr><td align="left">II</td><td align="left">485 (37%)</td><td align="left">433 (36%)</td><td align="left">40 (42%)</td><td align="left">13 (41%)</td><td align="left"/><td align="left">306 (31%)</td><td align="left">280 (31%)</td><td align="left">18 (36%)</td><td align="left">8 (36%)</td><td align="left"/></tr><tr><td align="left">III</td><td align="left">425 (32%)</td><td align="left">382 (32%)</td><td align="left">30 (32%)</td><td align="left">13 (41%)</td><td align="left"/><td align="left">346 (36%)</td><td align="left">325 (36%)</td><td align="left">16 (32%)</td><td align="left">5 (23%)</td><td align="left"/></tr><tr><td align="left">IV</td><td align="left">173 (13%)</td><td align="left">149 (12%)</td><td align="left">18 (19%)</td><td align="left">6 (19%)</td><td align="left"/><td align="left">108 (11%)</td><td align="left">94 (10%)</td><td align="left">8 (16%)</td><td align="left">6 (27%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>Tumor grade</italic></td></tr><tr><td align="left">Low-grade</td><td align="left">1106 (83%)</td><td align="left">1051 (87%)</td><td align="left">45 (47%)</td><td align="left">10 (31%)</td><td align="left">&#x0003c;0.001</td><td align="left">829 (85%)</td><td align="left">793 (88%)</td><td align="left">29 (58%)</td><td align="left">7 (32%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">High-grade</td><td align="left">223 (17%)</td><td align="left">151 (13%)</td><td align="left">50 (53%)</td><td align="left">22 (69%)</td><td align="left"/><td align="left">144 (15%)</td><td align="left">108 (12%)</td><td align="left">21 (42%)</td><td align="left">15 (68%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>Lymphovascular invasion</italic></td></tr><tr><td align="left">No</td><td align="left">1043 (78%)</td><td align="left">957 (80%)</td><td align="left">64 (67%)</td><td align="left">22 (69%)</td><td align="left">0.008</td><td align="left">509 (52%)</td><td align="left">478 (53%)</td><td align="left">24 (48%)</td><td align="left">7 (32%)</td><td align="left">0.118</td></tr><tr><td align="left">Yes</td><td align="left">286 (22%)</td><td align="left">245 (20%)</td><td align="left">31 (33%)</td><td align="left">10 (31%)</td><td align="left"/><td align="left">464 (48%)</td><td align="left">423 (47%)</td><td align="left">26 (52%)</td><td align="left">15 (68%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>MMR status</italic></td></tr><tr><td align="left">pMMR</td><td align="left">1160 (87%)</td><td align="left">1083 (90%)</td><td align="left">63 (66%)</td><td align="left">14 (44%)</td><td align="left">&#x0003c;0.001</td><td align="left">847 (87%)</td><td align="left">809 (90%)</td><td align="left">26 (52%)</td><td align="left">12 (55%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">dMMR</td><td align="left">169 (13%)</td><td align="left">119 (10%)</td><td align="left">32 (34%)</td><td align="left">18 (56%)</td><td align="left"/><td align="left">126 (13%)</td><td align="left">92 (10%)</td><td align="left">24 (48%)</td><td align="left">10 (45%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>BRAF status</italic></td></tr><tr><td align="left">Wild-type</td><td align="left">1140 (86%)</td><td align="left">1064 (89%)</td><td align="left">61 (64%)</td><td align="left">15 (47%)</td><td align="left">&#x0003c;0.001</td><td align="left">862 (89%)</td><td align="left">825 (92%)</td><td align="left">27 (54%)</td><td align="left">10 (45%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Mutant</td><td align="left">187 (4%)</td><td align="left">136 (11%)</td><td align="left">34 (36%)</td><td align="left">17 (53%)</td><td align="left"/><td align="left">111 (11%)</td><td align="left">76 (8%)</td><td align="left">23 (46%)</td><td align="left">12 (55%)</td><td align="left"/></tr><tr><td align="left" colspan="11"><italic>SATB2 subgroups</italic></td></tr><tr><td align="left">High</td><td align="left">1009 (76%)</td><td align="left">981 (82%)</td><td align="left">24 (25%)</td><td align="left">4 (13%)</td><td align="left">&#x0003c;0.001</td><td align="left">647 (67%)</td><td align="left">637 (71%)</td><td align="left">9 (18%)</td><td align="left">1 (5%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">Low</td><td align="left">265 (20%)</td><td align="left">194 (16%)</td><td align="left">53 (56%)</td><td align="left">18 (56%)</td><td align="left"/><td align="left">206 (21%)</td><td align="left">184 (20%)</td><td align="left">20 (40%)</td><td align="left">2 (9%)</td><td align="left"/></tr><tr><td align="left">Negative</td><td align="left">55 (4%)</td><td align="left">27 (2%)</td><td align="left">18 (19%)</td><td align="left">10 (31%)</td><td align="left"/><td align="left">120 (12%)</td><td align="left">80 (9%)</td><td align="left">21 (42%)</td><td align="left">19 (86%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: AJCC, The American Joint Committee on Cancer; RT/CRT, radiotherapy/chemoradiotherapy; MMR, mismatch repair; pMMR, mismatch repair proficient; and dMMR, mismatch repair deficient</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Associations between SATB2 expression and clinicopathological parameters in colorectal cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristic</th><th align="left" colspan="5">Cohort 1</th><th align="left" colspan="5">Cohort 2</th></tr><tr><th align="left">Total N</th><th align="left">High</th><th align="left">Low</th><th align="left">Negative</th><th align="left"><italic>p</italic></th><th align="left">Total N</th><th align="left">High</th><th align="left">Low</th><th align="left">Negative</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left">All cases</td><td align="left">1329 (100%)</td><td align="left">1009 (76%)</td><td align="left">265 (20%)</td><td align="left">55 (4%)</td><td char="." align="left"/><td align="left">973 (100%)</td><td align="left">647 (67%)</td><td align="left">206 (21%)</td><td align="left">120 (12%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>Sex</italic></td></tr><tr><td align="left">Female</td><td align="left">618 (47%)</td><td align="left">451 (%)</td><td align="left">131 (%)</td><td align="left">36 (%)</td><td align="left">&#x000a0;0.006</td><td align="left">425 (44%)</td><td align="left">272 (42%)</td><td align="left">99 (48%)</td><td align="left">54 (45%)</td><td char="." align="left">&#x000a0;0.302</td></tr><tr><td align="left">Male</td><td align="left">711 (54%)</td><td align="left">558 (%)</td><td align="left">134 (%)</td><td align="left">19 (%)</td><td char="." align="left"/><td align="left">548 (56%)</td><td align="left">375 (58%)</td><td align="left">107 (52%)</td><td align="left">66 (55%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>Age (years)</italic></td></tr><tr><td align="left">&#x0003c;65</td><td align="left">395 (30%)</td><td align="left">299 (30%)</td><td align="left">79 (30%)</td><td align="left">17 (31%)</td><td char="." align="left">&#x000a0;0.497</td><td align="left">330 (34%)</td><td align="left">216 (33%)</td><td align="left">73 (35%)</td><td align="left">41 (34%)</td><td align="left">&#x000a0;0.827</td></tr><tr><td align="left">65&#x02013;75</td><td align="left">454 (34%)</td><td align="left">357 (35%)</td><td align="left">81 (31%)</td><td align="left">16 (29%)</td><td char="." align="left"/><td align="left">356 (37%)</td><td align="left">240 (37%)</td><td align="left">69 (34%)</td><td align="left">47 (39%)</td><td align="left"/></tr><tr><td align="left">&#x0003e;75</td><td align="left">480 (36%)</td><td align="left">353 (35%)</td><td align="left">105 (40%)</td><td align="left">22 (40%)</td><td char="." align="left"/><td align="left">287 (29%)</td><td align="left">191 (30%)</td><td align="left">64 (31%)</td><td align="left">32 (27%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>Tumor location</italic></td></tr><tr><td align="left">Proximal colon</td><td align="left">532 (40%)</td><td align="left">352 (35%)</td><td align="left">139 (53%)</td><td align="left">41 (75%)</td><td align="left">&#x000a0;&#x0003c;0.001</td><td align="left">321 (33%)</td><td align="left">179 (28%)</td><td align="left">81 (39%)</td><td align="left">61 (51%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td></tr><tr><td align="left">Distal colon</td><td align="left">399 (30%)</td><td align="left">338 (34%)</td><td align="left">55 (21%)</td><td align="left">6 (11%)</td><td char="." align="left"/><td align="left">205 (21%)</td><td align="left">146 (23%)</td><td align="left">43 (21%)</td><td align="left">16 (13%)</td><td align="left"/></tr><tr><td align="left">Rectum</td><td align="left">398 (30%)</td><td align="left">319 (32%)</td><td align="left">71 (27%)</td><td align="left">8 (15%)</td><td char="." align="left"/><td align="left">447 (46%)</td><td align="left">322 (50%)</td><td align="left">82 (40%)</td><td align="left">43 (36%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>Preoperative RT/CRT</italic></td></tr><tr><td align="left"><p>No</p><p>Yes</p></td><td align="left"><p>1091 (82%)</p><p>239 (18%)</p></td><td align="left"><p>822 (82%)</p><p>187 (18%)</p></td><td align="left"><p>217 (82%)</p><p>49 (18%)</p></td><td align="left"><p>52 (95%)</p><p>3 (5%)</p></td><td char="." align="left"/><td align="left"><p>759 (78%)</p><p>214 (22%)</p></td><td align="left"><p>496 (77%)</p><p>151 (23%)</p></td><td align="left"><p>164 (80%)</p><p>42 (20%)</p></td><td align="left"><p>99 (83%)</p><p>21 (17%)</p></td><td char="." align="left">0.301</td></tr><tr><td align="left" colspan="11"><italic>AJCC disease stage</italic></td></tr><tr><td align="left">I</td><td align="left">246 (19%)</td><td align="left">212 (21%)</td><td align="left">27 (10%)</td><td align="left">6 (11%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td><td align="left">213 (22%)</td><td align="left">155 (24%)</td><td align="left">40 (19%)</td><td align="left">18 (15%)</td><td char="." align="left">&#x000a0;0.156</td></tr><tr><td align="left">II</td><td align="left">485 (37%)</td><td align="left">375 (37%)</td><td align="left">90 (34%)</td><td align="left">21 (38%)</td><td char="." align="left"/><td align="left">306 (31%)</td><td align="left">201 (31%)</td><td align="left">64 (31%)</td><td align="left">41 (34%)</td><td char="." align="left"/></tr><tr><td align="left">III</td><td align="left">425 (32%)</td><td align="left">306 (30%)</td><td align="left">102 (39%)</td><td align="left">17 (31%)</td><td char="." align="left"/><td align="left">346 (36%)</td><td align="left">229 (35%)</td><td align="left">75 (36%)</td><td align="left">42 (35%)</td><td char="." align="left"/></tr><tr><td align="left">IV</td><td align="left">173 (13%)</td><td align="left">116 (12%)</td><td align="left">46 (17%)</td><td align="left">11 (20%)</td><td char="." align="left"/><td align="left">108 (11%)</td><td align="left">62 (10%)</td><td align="left">27 (13%)</td><td align="left">19 (16%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>Tumor grade</italic></td></tr><tr><td align="left">Low-grade</td><td align="left">1106 (83%)</td><td align="left">896 (89%)</td><td align="left">181 (68%)</td><td align="left">29 (53%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td><td align="left">829 (85%)</td><td align="left">594 (92%)</td><td align="left">153 (74%)</td><td align="left">82 (68%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td></tr><tr><td align="left">High-grade</td><td align="left">223 (17%)</td><td align="left">113 (11%)</td><td align="left">84 (32%)</td><td align="left">26 (47%)</td><td char="." align="left"/><td align="left">144 (15%)</td><td align="left">53 (8%)</td><td align="left">53 (26%)</td><td align="left">38 (32%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>Lymphovascular invasion</italic></td></tr><tr><td align="left">No</td><td align="left">1043 (79%)</td><td align="left">813 (81%)</td><td align="left">187 (71%)</td><td align="left">43 (78%)</td><td char="." align="left">&#x000a0;0.002</td><td align="left">509 (52%)</td><td align="left">356 (55%)</td><td align="left">102 (50%)</td><td align="left">51 (43%)</td><td char="." align="left">&#x000a0;0.028</td></tr><tr><td align="left">Yes</td><td align="left">286 (22%)</td><td align="left">196 (19%)</td><td align="left">78 (29%)</td><td align="left">12 (22%)</td><td char="." align="left"/><td align="left">464 (48%)</td><td align="left">291 (45%)</td><td align="left">104 (51%)</td><td align="left">69 (58%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>MMR status</italic></td></tr><tr><td align="left">pMMR</td><td align="left">1160 (87%)</td><td align="left">913 (90%)</td><td align="left">209 (79%)</td><td align="left">38 (69%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td><td align="left">847 (87%)</td><td align="left">597 (92%)</td><td align="left">164 (80%)</td><td align="left">86 (72%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td></tr><tr><td align="left">dMMR</td><td align="left">169 (13%)</td><td align="left">96 (10%)</td><td align="left">56 (21%)</td><td align="left">17 (31%)</td><td char="." align="left"/><td align="left">126 (13%)</td><td align="left">50 (8%)</td><td align="left">42 (20%)</td><td align="left">34 (28%)</td><td char="." align="left"/></tr><tr><td align="left" colspan="11"><italic>BRAF status</italic></td></tr><tr><td align="left">Wild-type</td><td align="left">1140 (86%)</td><td align="left">911 (91%)</td><td align="left">189 (71%)</td><td align="left">40 (73%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td><td align="left">862 (89%)</td><td align="left">610 (94%)</td><td align="left">163 (79%)</td><td align="left">89 (74%)</td><td char="." align="left">&#x000a0;&#x0003c;0.001</td></tr><tr><td align="left">Mutant</td><td align="left">187 (4%)</td><td align="left">96 (10%)</td><td align="left">76 (29%)</td><td align="left">15 (27%)</td><td char="." align="left"/><td align="left">111 (11%)</td><td align="left">37 (6%)</td><td align="left">43 (21%)</td><td align="left">31 (26%)</td><td char="." align="left"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: AJCC, The American Joint Committee on Cancer; RT/CRT, radiotherapy/chemoradiotherapy; MMR, mismatch repair; pMMR, mismatch repair proficient; and dMMR, mismatch repair deficient</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Association with immune cell densities</title><p id="Par28">Next, we investigated whether the expression levels of CDX2 and SATB2 are associated with immune cell infiltration patterns of the tumors. We utilized three multiplex immunohistochemistry panels in Cohort 1 and conducted separate analyses for MMR-proficient (pMMR) and MMR-deficient (dMMR) tumors, considering that both immune cell densities and SATB2 and CDX2 expression are associated with MMR status. Example multiplex immunohistochemistry images of CDX2 high/SATB2 low tumor and their corresponding cell maps are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, while images of CDX2 high/SATB2 high tumor and CDX2 negative/SATB2 negative tumor are presented in Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>. We found several weak correlations between CDX2 and SATB2 histoscore and the overall densities of different immune cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). In pMMR tumors, lower CDX2 histoscore was associated with higher densities of macrophages (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.226, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), M2-like macrophages (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.197, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), mature monocytic cells (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.135, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), and immature monocytic cells (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.168, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Lower SATB2 histoscore was associated with decreased densities of M1-like macrophages (<italic>r</italic>&#x000a0;=&#x000a0;0.113, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and granulocytes (<italic>r</italic>&#x000a0;=&#x000a0;0.121, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and increased densities of macrophages (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.096, <italic>p</italic>&#x000a0;=&#x000a0;0.004), M2-like macrophages (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.164, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), and immature monocytic cells (<italic>r</italic>&#x000a0;=&#x000a0;<italic>&#x02212;</italic>0.130, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). In dMMR tumors, CDX2 expression showed no significant correlations with immune cells, while lower SATB2 expression was associated with decreased densities of M1-like macrophages (<italic>r</italic>&#x000a0;=&#x000a0;0.231, <italic>p</italic>&#x000a0;=&#x000a0;0.003) and mast cells (<italic>r</italic>&#x000a0;=&#x000a0;0.223, <italic>p</italic>&#x000a0;=&#x000a0;0.005). We further analyzed the correlations between CDX2/SATB2 expression and immune cell densities separately at the tumor center and at the invasive margin (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>), and the findings were largely similar to those for overall immune cell densities. To clarify the effects of the interaction between CDX2 loss and SATB2 loss on immune cell infiltration, we combined CDX2 expression status (high vs. low/negative) with SATB2 expression status (high vs. low/negative). CRCs with both CDX2 and SATB2 low/negative status had significantly lower M1-like macrophage and mast cell densities (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Immune cell analyses. <bold>A</bold>&#x02013;<bold>F</bold> Multiplex immunohistochemistry images for visualizing three staining panels (<bold>A</bold>, <bold>C</bold>, <bold>E</bold>) and their corresponding cell phenotyping maps (<bold>B</bold>, <bold>D</bold>, <bold>F</bold>) in one tumor core and a close-up view. Scale bars are 100&#x000a0;&#x000b5;m. <bold>G</bold>, <bold>H</bold> Two-dimensional visualization of the relationships between CDX2 and SATB2 expression levels and immune cell densities in mismatch repair-proficient (<bold>G</bold>) and -deficient (<bold>H</bold>) tumors in Cohort 1. The edges (connecting lines) depict the associations between variables (only those with <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01 are shown), and the edge length illustrates the significance of the association. The correlations between CDX2 and SATB2 and other variables are represented by green (positive correlation) and red (negative correlation) edges, with the label showing corresponding Spearman correlation coefficient for the correlation. The other associations are represented by gray edges</p></caption><graphic xlink:href="262_2025_3964_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9"><title>Survival analyses</title><p id="Par29">Finally, we analyzed the prognostic value of CDX2 and SATB2 immunohistochemistry. There were 354 cancer deaths in Cohort 1 and 196 in Cohort 2. Kaplan-Meier plots showed that low CDX2 and SATB2 levels predicted shorter CSS compared to high levels in both cohorts (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 for all, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The prognostic significance of CDX2 remained after adjusting for other confounding factors in multivariable Cox regression models in both cohorts (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). The multivariable HR for negative (vs. high) CDX2 expression was 3.62 (95% CI 2.08&#x02013;6.31, <italic>p</italic><sub>trend</sub>&#x000a0;&#x0003c;&#x000a0;0.0001) in Cohort 1 and 3.55 (95% CI 1.72&#x02013;7.31, <italic>p</italic><sub>trend</sub>&#x000a0;&#x0003c;&#x000a0;0.0001) in Cohort 2. For SATB2, a trend of an association between low expression and worse survival was observed in multivariable Cox regression model in Cohort 1 (HR for negative vs. high SATB2 level 1.61, 95% CI 0.97&#x02013;2.67, <italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.002) and a significant association in Cohort 2 (HR for negative vs. high SATB2 level 1.75, 95% CI 1.15&#x02013;2.67, <italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.007) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). When we analyzed the survival according to combined CDX2/SATB2 expression category variable, patients with low/negative expression of both CDX2 and SATB2 showed the worst survival outcomes (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S4</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Survival analyses. Kaplan&#x02013;Meier analysis and log-rank test of colorectal cancer-specific survival according to CDX2 expression in Cohort 1 (<bold>A</bold>) and Cohort 2 (<bold>B</bold>) and SATB2 expression in Cohort 1 (<bold>C</bold>) and Cohort 2 (<bold>D</bold>)</p></caption><graphic xlink:href="262_2025_3964_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Cancer-specific survival according to CDX2 and SATB2 expression in Cohort 1 and 2</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Cohort 1</th><th align="left" colspan="4">Cohort 2</th></tr><tr><th align="left">No. of cases</th><th align="left">No. of events</th><th align="left">Univariable HR (95% CI)</th><th align="left">Multivariable HR (95% CI)</th><th align="left">No. of cases</th><th align="left">No. of events</th><th align="left">Univariable HR (95% CI)</th><th align="left">Multivariable HR (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="9"><italic>CDX2</italic></td></tr><tr><td align="left">High</td><td align="left">1168</td><td align="left">305</td><td align="left">1 (referent)</td><td align="left">1 (referent)</td><td align="left">896</td><td align="left">171</td><td align="left">1 (referent)</td><td align="left">1 (referent)</td></tr><tr><td align="left">Low</td><td align="left">91</td><td align="left">33</td><td align="left">1.68 (1.18&#x02013;2.41)</td><td align="left">1.88 (1.23&#x02013;2.81)</td><td align="left">50</td><td align="left">14</td><td align="left">1.51 (0.87&#x02013;2.60)</td><td align="left">1.25 (0.67&#x02013;2.32)</td></tr><tr><td align="left">Negative</td><td align="left">30</td><td align="left">16</td><td align="left">2.90 (1.75&#x02013;4.80)</td><td align="left">3.62 (2.08&#x02013;6.31)</td><td align="left">22</td><td align="left">11</td><td align="left">3.86 (2.10&#x02013;7.10)</td><td align="left">3.55 (1.72&#x02013;7.31)</td></tr><tr><td align="left"><italic>p</italic><sub>trend</sub></td><td align="left"/><td align="left"/><td align="left">&#x0003c;0.0001</td><td align="left">&#x0003c;0.0001</td><td align="left"/><td align="left"/><td align="left">&#x0003c;0.0001</td><td align="left">0.003</td></tr><tr><td align="left" colspan="9"><italic>SATB2</italic></td></tr><tr><td align="left">High</td><td align="left">981</td><td align="left">241</td><td align="left">1 (referent)</td><td align="left">1 (referent)</td><td align="left">645</td><td align="left">108</td><td align="left">1 (referent)</td><td align="left">1 (referent)</td></tr><tr><td align="left">Low</td><td align="left">255</td><td align="left">95</td><td align="left">1.82 (1.44&#x02013;2.31)</td><td align="left">1.47 (1.15&#x02013;1.89)</td><td align="left">204</td><td align="left">52</td><td align="left">1.45 (1.04&#x02013;2.02)</td><td align="left">1.32 (0.93&#x02013;1.89)</td></tr><tr><td align="left">Negative</td><td align="left">53</td><td align="left">18</td><td align="left">1.72 (1.07&#x02013;2.78)</td><td align="left">1.61 (0.97&#x02013;2.67)</td><td align="left">119</td><td align="left">36</td><td align="left">1.86 (1.28&#x02013;2.72)</td><td align="left">1.75 (1.15&#x02013;2.67)</td></tr><tr><td align="left"><italic>p</italic><sub>trend</sub></td><td align="left"/><td align="left"/><td align="left">&#x0003c;0.0001</td><td align="left">0.002</td><td align="left"/><td align="left"/><td align="left">0.0005</td><td align="left">0.007</td></tr></tbody></table><table-wrap-foot><p>Multivariable Cox proportional hazards regression models were adjusted for sex, age (&#x0003c;&#x000a0;65, 65&#x02013;75, and &#x0003e;&#x000a0;75), year of operation (Cohort 1: 2000&#x02013;2005, 2006&#x02013;2010, and 2011&#x02013;2015, Cohort 2: 2006&#x02013;2010, 2011&#x02013;2015, and 2016&#x02013;2020), tumor location (proximal colon, distal colon, and rectum), disease stage (I, II, III, and IV), tumor grade (well/moderately differentiated and poorly differentiated), lymphovascular invasion (negative and positive), MMR status (proficient and deficient), <italic>BRAF</italic> status (wild-type and mutant), and preoperative radiotherapy or chemoradiotherapy (no and yes)</p><p><italic>p</italic><sub>trend</sub> values were calculated by using the three ordinal categories of CDX2 histoscore and SATB2 histoscore as continuous variables in univariable and multivariable Cox proportional hazard regression models</p><p>CI confidence interval and HR hazard ratio</p></table-wrap-foot></table-wrap></p><p id="Par30">To compare the prognostic value of CDX2 and SATB2 histoscore and immune cell score, we included these variables in the same multivariable Cox regression models (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S4</xref>). In these models, CDX2 histoscore had prognostic value in both cohorts (<italic>p</italic><sub>trend</sub>&#x000a0;&#x0003c;&#x000a0;0.0001 in Cohort 1 and <italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.0005 in Cohort 2) independently of immune cell score (<italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.001 in Cohort 1 and <italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.002 in Cohort 2). Additionally, CDX2/SATB2 combination variable had prognostic value independent of immune cell score. The prognostic value of SATB2 histoscore remained in the multivariable model including immune cell score in Cohort 1 (<italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.0004), but not in Cohort 2 (<italic>p</italic><sub>trend</sub>&#x000a0;=&#x000a0;0.019). Subgroup analyses were performed to further assess the prognostic significance of CDX2 and SATB2 expression status according to various clinicopathologic features (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S6</xref>), but no consistent findings of a significant difference according to any clinicopathologic characteristic were discovered across both cohorts.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par31">We evaluated the associations of CDX2 and SATB2 expression with immune cell infiltration and prognosis in two large CRC cohorts. We found that reduced CDX2 and SATB2 expression were associated with increased infiltration of myeloid cells, most prominently immature monocytic cells and M2-like macrophages, in pMMR tumors, while reduced SATB2 expression in dMMR tumors was associated with lower infiltration of M1-like macrophages and mast cells. Lower CDX2 expression predicted worse CSS in both cohorts independent of conventional prognostic parameters and immune cell infiltrates. These findings underscore the potential of CDX2 and SATB2 as biomarkers for stratifying CRC patients and highlight their significance in regulating the tumor microenvironment, which could inform the development of targeted therapies.</p><p id="Par32">As CDX2 and SATB2 have been linked to intestinal inflammation, we hypothesized that loss of CDX2 and SATB2 expression might be associated with alterations in immune cell infiltration patterns in CRC. We found that both lower CDX2 and SATB2 expression were associated with increased macrophage, M2-like macrophage, and immature monocytic cell infiltrates in pMMR tumors. In addition, lower CDX2 expression was associated with increased mature monocytic cell densities and lower SATB expression with decreased M1-like macrophage and granulocyte densities. In dMMR tumors, lower SATB2 expression was associated with decreased densities of M1-like macrophages and mast cells. In combined analyses that included both CDX2 and SATB2 status, CRCs with low/negative expression of both CDX2 and SATB2 had significantly lower densities of M1-like macrophages and mast cells. Although the correlations were weak, these findings provide new insights into the potential role of CDX2 and SATB2 in CRC-associated inflammatory reactions. Previously, only a few studies have examined the associations between tumor-infiltrating immune cells and the expression of CDX2 or SATB2 in CRC. Chewchuk et al. [<xref ref-type="bibr" rid="CR32">32</xref>] demonstrated that loss of Cdx function leads to attenuation of histocompatibility complex protein H2-T3, followed by a decrease in iCD8&#x003b1; cell number and degranulation, and an increase in macrophage infiltration in the murine intestinal epithelium. Our results align with this finding, as CDX2 expression showed a negative correlation with macrophage densities. Wang et al. have also reported a negative association between the expression of CDX2 and tumor-infiltrating macrophages [<xref ref-type="bibr" rid="CR22">22</xref>]. However, they also showed a negative association between CDX2 expression and T-cell infiltrate, whereas we found no correlation between T-cell density and CDX2 or SATB2 expression status. Ni et al. [<xref ref-type="bibr" rid="CR23">23</xref>] studied colitis model in intestinal epithelial-specific Satb2 knockout mice and control mice, and observed higher numbers of M1 macrophages in Satb2 knockout mice. In contrast with this, we found that lower SATB2 expression was associated with decreased M1-like macrophage infiltrate. Our results suggest that CDX2 and SATB2 expression could affect myeloid cell recruitment and macrophage balance (M1 vs. M2). While the underlying mechanisms remain hypothetical, it is possible that loss of CDX2/SATB2 expression leads to increased expression of cytokines that drive macrophage polarization toward M2 phenotype [<xref ref-type="bibr" rid="CR21">21</xref>]. Additionally, the associations with altered immune cell densities might be related to disruption of the intestinal epithelial barrier, as CDX2 is essential for maintaining its integrity and function [<xref ref-type="bibr" rid="CR1">1</xref>]. Compared to the previous studies, our analyses benefited from the use of multiplex immunohistochemistry that enabled more precise detection of different immune cell types. For example, there are no single specific markers for macrophage polarization states [<xref ref-type="bibr" rid="CR33">33</xref>], and our method was based on calculating a polarization index based on the expression of four polarization markers.</p><p id="Par33">Reduced CDX2 expression was an independent factor for worse CSS in multivariable analysis in both cohorts, whereas reduced SATB2 expression was independent prognostic factor in one cohort and showed a trend of an association in the other cohort. Previously, CDX2 loss has been identified as an independent poor prognostic factor in both non-metastatic and metastatic CRC [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] although not all studies have confirmed its prognostic value [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Independent prognostic significance of SATB2 expression has also been reported [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Schmitt et al. [<xref ref-type="bibr" rid="CR8">8</xref>] previously reported a higher prognostic value for SATB2 loss compared to CDX2 loss, whereas we found that the prognostic impact of CDX2 loss was higher compared to SATB2 loss. Lee et al. [<xref ref-type="bibr" rid="CR38">38</xref>] analyzed concomitant expression patterns of CDX2 and SATB2 as prognostic factors and found that concomitant loss of CDX2 and SATB2, but not isolated loss of CDX2 or SATB2, is a prognostic marker for stage III CRCs. The prognostic significance of CDX2 and SATB2 may be different in specific subgroups such as pMMR and dMMR tumors. Most studies have reported a prognostic value for CDX2 in pMMR tumors [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], while Ma et al. [<xref ref-type="bibr" rid="CR35">35</xref>] reported an impact only in patients with dMMR but not pMMR tumors. In our subgroup analyses, we found no statistically significant difference in the prognostic significance of CDX2 or SATB2 according to MMR status. Considering that CDX2 and SATB2 expression were associated with immune cell infiltration patterns, we also compared their prognostic value with the immune cell score. In this analysis, the prognostic significance of CDX2 and CDX2/SATB2 combination variable remained independent of immune cell score in both cohorts.</p><p id="Par34">The frequency of CDX2 loss was 2% and SATB2 loss 4&#x02013;12% in the two cohorts. These findings are in line with the previous studies reporting CDX2 loss in 1.3&#x02013;5.9% and SATB2 loss in 6.6&#x02013;28.8% of CRCs [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. These results support the applicability of both transcription factors as markers of tumors with colorectal origin. When applying these markers in the diagnostics of tumors of uncertain origin, it needs to be noted that loss of CDX2 and SATB2 expression was associated with higher tumor grade, proximal tumor location, <italic>BRAF</italic> mutation, and dMMR, which also corresponds with the findings of the previous studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. While CDX2 appears to have somewhat higher sensitivity for CRC than SATB2, the previous studies have indicated that SATB2 has higher specificity for CRC, as CDX2 is frequently also expressed by adenocarcinomas of the pancreas or the upper gastrointestinal tract among others [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par35">This study has some limitations. First, protein expression is heterogeneous in tumor tissue, and we used TMAs, which only represent small areas of the tumor. However, the previous studies have shown the applicability of TMAs in the analysis of immune cell infiltrates in CRC [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, CDX2 and SATB2 expression generally showed little variation between cores sampled from different parts of the tumors. Second, data on cancer adjuvant treatments were not available, and we could not assess whether CDX2 or SATB2 expression would predict response to specific treatments. The strengths of this study include the utilization of two large CRC cohorts that contained extensive clinicopathologic data. The immune cell analyses were stratified by MMR status which is an important confounding factor that is associated with both immune cell densities and CDX2/SATB2 expression. Supervised machine learning technique facilitated quantitative image analysis and provided more accurate estimates of protein expression levels in comparison with visual evaluation.</p><p id="Par36">In conclusion, reduced CDX2 and SATB2 expression are associated with increased infiltration of myeloid cells in pMMR tumors and exhibit unfavorable prognostic effect in CRC. These findings support the role of CDX2 and SATB2 in regulating the tumor microenvironment, as well as their potential as prognostic biomarkers in CRC.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="262_2025_3964_MOESM1_ESM.pdf"><caption><p>Supplementary file1 (PDF 1436 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AJCC</term><def><p id="Par5">The American Joint Committee on Cancer</p></def></def-item><def-item><term>CDX2</term><def><p id="Par6">Caudal-type homeobox 2</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence interval</p></def></def-item><def-item><term>CRC</term><def><p id="Par8">Colorectal cancer</p></def></def-item><def-item><term>CSS</term><def><p id="Par9">Cancer-specific survival</p></def></def-item><def-item><term>CT</term><def><p id="Par10">Center of the tumor</p></def></def-item><def-item><term>dMMR</term><def><p id="Par11">Mismatch repair deficient</p></def></def-item><def-item><term>HR</term><def><p id="Par12">Hazard ratio</p></def></def-item><def-item><term>IM</term><def><p id="Par13">Invasive margin</p></def></def-item><def-item><term>MMR</term><def><p id="Par14">Mismatch repair</p></def></def-item><def-item><term>pMMR</term><def><p id="Par15">Mismatch repair proficient</p></def></def-item><def-item><term>RT/CRT</term><def><p id="Par16">Radiotherapy/chemoradiotherapy</p></def></def-item><def-item><term>SATB2</term><def><p id="Par17">Special AT-rich sequence-binding protein 2</p></def></def-item><def-item><term>TMA</term><def><p id="Par18">Tissue microarray</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We acknowledge Dr. Sara V&#x000e4;yrynen for her contribution to the immune cell analyses, particularly for providing the image co-registration script that enabled multiplex immunohistochemical analyses. The study benefited from samples/data from Central Finland Biobank (Jyv&#x000e4;skyl&#x000e4;, Finland) and Northern Finland Biobank Borealis (Oulu, Finland).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>P. Sirni&#x000f6; and J. P. V&#x000e4;yrynen conceptualized the study. P. Sirni&#x000f6;, H. Elomaa, A. Tuomisto, V. K. &#x000c4;ij&#x000e4;l&#x000e4;, H. Karjalainen, M. Kastinen, V. V. Tapiainen, O. Sirki&#x000e4;, and J. P. V&#x000e4;yrynen curated the data. P. Sirni&#x000f6; and J. P. V&#x000e4;yrynen performed formal analysis. M. J. M&#x000e4;kinen and J. P. V&#x000e4;yrynen acquired funding. All authors participated in investigation. P. Sirni&#x000f6; and J. P. V&#x000e4;yrynen contributed to the methodology. J. P. V&#x000e4;yrynen supervised the study. P. Sirni&#x000f6; and J. P. V&#x000e4;yrynen performed visualization. P. Sirni&#x000f6; and J. P. V&#x000e4;yrynen drafted the manuscript. All authors contributed to manuscript&#x000a0;review and editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided by University of Oulu (including Oulu University Hospital). The study was funded by Cancer Foundation Finland (59-5619 to JPV), Emil Aaltonen Foundation (220257P to JPV), Finnish Medical Foundation (6021 to JPV), Sigrid Jus&#x000e9;lius Foundation (230229 to JPV), and Finnish State Research Funding (to MJM and JPV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data generated and/or analyzed during this study are not publicly available. The sharing of data will require approval from relevant ethics committees and/or biobanks. Further information including the procedures to obtain and access data of Finnish Biobanks are described at <ext-link ext-link-type="uri" xlink:href="https://finbb.fi/en/fingenious-service">https://finbb.fi/en/fingenious-service</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par37">T.T. Sepp&#x000e4;l&#x000e4; reports consultation fees from Tillots Pharma, Mehil&#x000e4;inen and Nouscom, being a co-owner and CEO of Healthfund Finland Ltd., and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. The other authors declare that they have no conflicts of interest.</p></notes><notes id="FPar2"><title>Compliance with ethical standards</title><p id="Par38">The study was performed according to the guidelines of the Declaration of Helsinki. For Cohort 1, the study was approved by the Regional medical research ethics committee of the Well-being services county of Central Finland (Dnro13U/2011, 1/2016, 8/2020, and 2/2023), the Finnish Medicines Agency (Fimea), and the Central Finland Biobank (BB23-0172). The need to obtain informed consent from the study patients was waived (FIMEA/2023/001573, 4/2023). For Cohort 2, the study was approved by the Regional medical research ethics committee of the Well-being services county of North Ostrobothnia (25/2002, 42/2005, 122/2009, and 37/2020), Fimea (FIMEA/2022/001941), and Biobank Borealis (BB-2017_1012). Patients signed an informed consent to participate.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>F</given-names></name></person-group><article-title>The role of Cdx genes in the mammalian gut</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1394</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.038240</pub-id><pub-id pub-id-type="pmid">15361482</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Beck F (2004) The role of Cdx genes in the mammalian gut. Gut 53:1394&#x02013;6. 10.1136/gut.2003.038240<pub-id pub-id-type="pmid">15361482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Pakvasa</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>SATB2: A versatile transcriptional regulator of craniofacial and skeleton development, neurogenesis and tumorigenesis, and its applications in regenerative medicine</article-title><source>Genes Dis</source><year>2020</year><volume>9</volume><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/J.GENDIS.2020.10.003</pub-id><pub-id pub-id-type="pmid">35005110</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Huang X, Chen Q, Luo W, Pakvasa M, Zhang Y, Zheng L et al (2020) SATB2: A versatile transcriptional regulator of craniofacial and skeleton development, neurogenesis and tumorigenesis, and its applications in regenerative medicine. Genes Dis 9:95&#x02013;107. 10.1016/J.GENDIS.2020.10.003<pub-id pub-id-type="pmid">35005110</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Kraiczy</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>PNP</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><etal/></person-group><article-title>SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling</article-title><source>Cell Stem Cell</source><year>2022</year><volume>29</volume><fpage>101</fpage><lpage>115.e10</lpage><pub-id pub-id-type="doi">10.1016/J.STEM.2021.09.004</pub-id><pub-id pub-id-type="pmid">34582804</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C et al (2022) SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling. Cell Stem Cell 29:101-115.e10. 10.1016/J.STEM.2021.09.004<pub-id pub-id-type="pmid">34582804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Werling</surname><given-names>RW</given-names></name><name><surname>Yaziji</surname><given-names>H</given-names></name><name><surname>Bacchi</surname><given-names>CE</given-names></name><name><surname>Gown</surname><given-names>AM</given-names></name></person-group><article-title>CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas</article-title><source>Am J Surg Pathol</source><year>2003</year><volume>27</volume><fpage>303</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/00000478-200303000-00003</pub-id><pub-id pub-id-type="pmid">12604886</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27:303&#x02013;10. 10.1097/00000478-200303000-00003<pub-id pub-id-type="pmid">12604886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y-J</given-names></name><name><surname>Chen</surname><given-names>J-W</given-names></name><name><surname>He</surname><given-names>X-S</given-names></name><name><surname>Zhang</surname><given-names>H-Z</given-names></name><name><surname>Ling</surname><given-names>Y-H</given-names></name><name><surname>Wen</surname><given-names>J-H</given-names></name><etal/></person-group><article-title>SATB2 is a promising biomarker for identifying a colorectal origin for liver metastatic adenocarcinomas</article-title><source>EBioMedicine</source><year>2018</year><volume>28</volume><fpage>62</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.01.001</pub-id><pub-id pub-id-type="pmid">29396302</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Zhang Y-J, Chen J-W, He X-S, Zhang H-Z, Ling Y-H, Wen J-H et al (2018) SATB2 is a promising biomarker for identifying a colorectal origin for liver metastatic adenocarcinomas. EBioMedicine 28:62&#x02013;9. 10.1016/j.ebiom.2018.01.001<pub-id pub-id-type="pmid">29396302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Dragomir</surname><given-names>A</given-names></name><name><surname>de Wit</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Pont&#x000e9;n</surname><given-names>F</given-names></name></person-group><article-title>The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study</article-title><source>Am J Clin Pathol</source><year>2014</year><volume>141</volume><fpage>630</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1309/AJCPWW2URZ9JKQJU</pub-id><pub-id pub-id-type="pmid">24713733</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Dragomir A, de Wit M, Johansson C, Uhlen M, Pont&#x000e9;n F (2014) The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol 141:630&#x02013;8. 10.1309/AJCPWW2URZ9JKQJU<pub-id pub-id-type="pmid">24713733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>J</given-names></name><name><surname>Espersen</surname><given-names>MLM</given-names></name><name><surname>Jess</surname><given-names>P</given-names></name><name><surname>Kirkeby</surname><given-names>LT</given-names></name><name><surname>Troelsen</surname><given-names>JT</given-names></name></person-group><article-title>The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review</article-title><source>Surg Oncol</source><year>2014</year><volume>23</volume><fpage>167</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.suronc.2014.07.003</pub-id><pub-id pub-id-type="pmid">25126956</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Olsen J, Espersen MLM, Jess P, Kirkeby LT, Troelsen JT (2014) The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. Surg Oncol 23:167&#x02013;76. 10.1016/j.suronc.2014.07.003<pub-id pub-id-type="pmid">25126956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Konukiewitz</surname><given-names>B</given-names></name><name><surname>Lang</surname><given-names>C</given-names></name><name><surname>Steiger</surname><given-names>K</given-names></name><name><surname>Halfter</surname><given-names>K</given-names></name><etal/></person-group><article-title>Loss of SATB2 occurs more frequently than CDX2 loss in colorectal carcinoma and identifies particularly aggressive cancers in high-risk subgroups</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><fpage>6177</fpage><pub-id pub-id-type="doi">10.3390/cancers13246177</pub-id><pub-id pub-id-type="pmid">34944797</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Schmitt M, Silva M, Konukiewitz B, Lang C, Steiger K, Halfter K et al (2021) Loss of SATB2 occurs more frequently than CDX2 loss in colorectal carcinoma and identifies particularly aggressive cancers in high-risk subgroups. Cancers (Basel) 13:6177. 10.3390/cancers13246177<pub-id pub-id-type="pmid">34944797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Cho</surname><given-names>N-Y</given-names></name><name><surname>Kim</surname><given-names>T-Y</given-names></name><name><surname>Kang</surname><given-names>GH</given-names></name></person-group><article-title>Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>1457</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i5.1457</pub-id><pub-id pub-id-type="pmid">25663765</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bae JM, Lee TH, Cho N-Y, Kim T-Y, Kang GH (2015) Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol 21:1457&#x02013;67. 10.3748/wjg.v21.i5.1457<pub-id pub-id-type="pmid">25663765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhard</surname><given-names>J</given-names></name><name><surname>Gaber</surname><given-names>A</given-names></name><name><surname>Wangefjord</surname><given-names>S</given-names></name><name><surname>Nodin</surname><given-names>B</given-names></name><name><surname>Uhl&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Ericson Lindquist</surname><given-names>K</given-names></name><etal/></person-group><article-title>A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer</article-title><source>Br J Cancer</source><year>2012</year><volume>106</volume><fpage>931</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.34</pub-id><pub-id pub-id-type="pmid">22333599</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhl&#x000e9;n M, Ericson Lindquist K et al (2012) A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer 106:931&#x02013;8. 10.1038/bjc.2012.34<pub-id pub-id-type="pmid">22333599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Sahoo</surname><given-names>D</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Yothers</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><etal/></person-group><article-title>CDX2 as a prognostic biomarker in Stage II and Stage III colon cancer</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>211</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1506597</pub-id><pub-id pub-id-type="pmid">26789870</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N et al (2016) CDX2 as a prognostic biomarker in Stage II and Stage III colon cancer. N Engl J Med 374:211&#x02013;22. 10.1056/NEJMoa1506597<pub-id pub-id-type="pmid">26789870</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Heinemann</surname><given-names>V</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name><name><surname>Stintzing</surname><given-names>S</given-names></name></person-group><article-title>The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer</article-title><source>Virchows Arch</source><year>2018</year><volume>473</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1007/S00428-018-2360-Y</pub-id><pub-id pub-id-type="pmid">29675807</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Neumann J, Heinemann V, Engel J, Kirchner T, Stintzing S (2018) The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. Virchows Arch 473:199&#x02013;207. 10.1007/S00428-018-2360-Y<pub-id pub-id-type="pmid">29675807</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Aaseb&#x000f8;</surname><given-names>K</given-names></name><name><surname>Dragomir</surname><given-names>A</given-names></name><name><surname>Sundstr&#x000f6;m</surname><given-names>M</given-names></name><name><surname>Mezheyeuski</surname><given-names>A</given-names></name><name><surname>Edqvist</surname><given-names>P-H</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><etal/></person-group><article-title>CDX2: a prognostic marker in metastatic colorectal cancer defining a better BRAF mutated and a worse KRAS mutated subgroup</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00008</pub-id><pub-id pub-id-type="pmid">32117703</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Aaseb&#x000f8; K, Dragomir A, Sundstr&#x000f6;m M, Mezheyeuski A, Edqvist P-H, Eide GE et al (2020) CDX2: a prognostic marker in metastatic colorectal cancer defining a better BRAF mutated and a worse KRAS mutated subgroup. Front Oncol 10:8. 10.3389/fonc.2020.00008<pub-id pub-id-type="pmid">32117703</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Konukiewitz</surname><given-names>B</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Pohl</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>C</given-names></name><name><surname>Steiger</surname><given-names>K</given-names></name><etal/></person-group><article-title>Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification</article-title><source>Br J Cancer</source><year>2021</year><volume>125</volume><fpage>1632</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01553-0</pub-id><pub-id pub-id-type="pmid">34616012</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Konukiewitz B, Schmitt M, Silva M, Pohl J, Lang C, Steiger K et al (2021) Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification. Br J Cancer 125:1632&#x02013;46. 10.1038/s41416-021-01553-0<pub-id pub-id-type="pmid">34616012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Olevian</surname><given-names>DC</given-names></name><name><surname>Lowenthal</surname><given-names>BM</given-names></name><name><surname>Jayachandran</surname><given-names>P</given-names></name><name><surname>Kozak</surname><given-names>MM</given-names></name><name><surname>Chang</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Loss of SATB2 expression in colorectal carcinoma is associated With DNA mismatch repair protein deficiency and BRAF mutation</article-title><source>Am J Surg Pathol</source><year>2018</year><volume>42</volume><fpage>1409</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001116</pub-id><pub-id pub-id-type="pmid">30001238</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ma C, Olevian DC, Lowenthal BM, Jayachandran P, Kozak MM, Chang DT et al (2018) Loss of SATB2 expression in colorectal carcinoma is associated With DNA mismatch repair protein deficiency and BRAF mutation. Am J Surg Pathol 42:1409&#x02013;17. 10.1097/PAS.0000000000001116<pub-id pub-id-type="pmid">30001238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Vlahovi&#x00107;</surname><given-names>I</given-names></name><name><surname>Rajc</surname><given-names>J</given-names></name><name><surname>&#x00160;vagelj</surname><given-names>I</given-names></name><name><surname>&#x00160;oli&#x00107;</surname><given-names>K</given-names></name><name><surname>&#x00160;vagelj</surname><given-names>D</given-names></name></person-group><article-title>Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer</article-title><source>Pathol Oncol Res</source><year>2023</year><volume>29</volume><fpage>1610908</fpage><pub-id pub-id-type="doi">10.3389/PORE.2023.1610908</pub-id><pub-id pub-id-type="pmid">37325467</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Vlahovi&#x00107; I, Rajc J, &#x00160;vagelj I, &#x00160;oli&#x00107; K, &#x00160;vagelj D (2023) Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer. Pathol Oncol Res 29:1610908. 10.3389/PORE.2023.1610908<pub-id pub-id-type="pmid">37325467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>PG</given-names></name><name><surname>Mcmillan</surname><given-names>DC</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name></person-group><article-title>Systematic or meta-analysis studies the local inflammatory response in colorectal cancer-type, location or density?</article-title><source>Cancer treatment reviews</source><year>2020</year><volume>83</volume><fpage>101949</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2019.101949</pub-id><pub-id pub-id-type="pmid">31869737</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Alexander PG, Mcmillan DC, Park JH (2020) The local inflammatory response in colorectal cancer - Type, location or density? A systematic review and meta-analysis. Cancer Treat Rev 83:101949.&#x000a0;10.1016/j.ctrv.2019.101949<pub-id pub-id-type="pmid">31869737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Angell</surname><given-names>HK</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Lagorce</surname><given-names>C</given-names></name><etal/></person-group><article-title>Towards the introduction of the &#x0201c;Immunoscore&#x0201d; in the classification of malignant tumours</article-title><source>J Pathol</source><year>2014</year><volume>232</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1002/path.4287</pub-id><pub-id pub-id-type="pmid">24122236</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C et al (2014) Towards the introduction of the &#x0201c;Immunoscore&#x0201d; in the classification of malignant tumours. J Pathol 232:199&#x02013;209. 10.1002/path.4287<pub-id pub-id-type="pmid">24122236</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Pag&#x000e8;s</surname><given-names>F</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Thurin</surname><given-names>M</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>BA</given-names></name><etal/></person-group><article-title>The immune score as a new possible approach for the classification of cancer</article-title><source>J Transl Med</source><year>2012</year><volume>10</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-10-1</pub-id><pub-id pub-id-type="pmid">22214470</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Galon J, Pag&#x000e8;s F, Marincola FM, Thurin M, Trinchieri G, Fox BA et al (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1. 10.1186/1479-5876-10-1<pub-id pub-id-type="pmid">22214470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Jahan</surname><given-names>S</given-names></name><name><surname>Awaja</surname><given-names>N</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Hajjar</surname><given-names>S</given-names></name><name><surname>Sad</surname><given-names>S</given-names></name><name><surname>Lohnes</surname><given-names>D</given-names></name></person-group><article-title>The transcription factor Cdx2 regulates inflammasome activity through expression of the NLRP3 suppressor TRIM31 to maintain intestinal homeostasis</article-title><source>J Biol Chem</source><year>2022</year><volume>298</volume><fpage>102386</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102386</pub-id><pub-id pub-id-type="pmid">35985421</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jahan S, Awaja N, Hess B, Hajjar S, Sad S, Lohnes D (2022) The transcription factor Cdx2 regulates inflammasome activity through expression of the NLRP3 suppressor TRIM31 to maintain intestinal homeostasis. J Biol Chem 298:102386. 10.1016/j.jbc.2022.102386<pub-id pub-id-type="pmid">35985421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Balbinot</surname><given-names>C</given-names></name><name><surname>Armant</surname><given-names>O</given-names></name><name><surname>Elarouci</surname><given-names>N</given-names></name><name><surname>Marisa</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>De Clara</surname><given-names>E</given-names></name><etal/></person-group><article-title>The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms</article-title><source>J Exp Med</source><year>2018</year><volume>215</volume><fpage>911</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1084/jem.20170934</pub-id><pub-id pub-id-type="pmid">29439001</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Balbinot C, Armant O, Elarouci N, Marisa L, Martin E, De Clara E et al (2018) The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms. J Exp Med 215:911&#x02013;26. 10.1084/jem.20170934<pub-id pub-id-type="pmid">29439001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y-S</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>R-T</given-names></name><name><surname>Han</surname><given-names>B-W</given-names></name><name><surname>Li</surname><given-names>C-H</given-names></name><name><surname>Wang</surname><given-names>H-J</given-names></name><etal/></person-group><article-title>CDX2 as a predictive biomarker involved in immunotherapy response suppresses metastasis through EMT in colorectal cancer</article-title><source>Dis Markers</source><year>2022</year><volume>2022</volume><fpage>9025668</fpage><pub-id pub-id-type="doi">10.1155/2022/9025668</pub-id><pub-id pub-id-type="pmid">36277982</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang Y-S, Kou Y, Zhu R-T, Han B-W, Li C-H, Wang H-J et al (2022) CDX2 as a predictive biomarker involved in immunotherapy response suppresses metastasis through EMT in colorectal cancer. Dis Markers 2022:9025668. 10.1155/2022/9025668<pub-id pub-id-type="pmid">36277982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group><article-title>SATB2 defect promotes colitis and colitis-associated colorectal cancer by impairing Cl-/HCO3- exchange and homeostasis of gut microbiota</article-title><source>J Crohns Colitis</source><year>2021</year><volume>15</volume><fpage>2088</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1093/ECCO-JCC/JJAB094</pub-id><pub-id pub-id-type="pmid">34019628</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ni H, Chen Y, Xia W, Wang C, Hu C, Sun L et al (2021) SATB2 defect promotes colitis and colitis-associated colorectal cancer by impairing Cl-/HCO3- exchange and homeostasis of gut microbiota. J Crohns Colitis 15:2088&#x02013;102. 10.1093/ECCO-JCC/JJAB094<pub-id pub-id-type="pmid">34019628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Coskun</surname><given-names>M</given-names></name><name><surname>Olsen</surname><given-names>AK</given-names></name><name><surname>Holm</surname><given-names>TL</given-names></name><name><surname>Kvist</surname><given-names>PH</given-names></name><name><surname>Nielsen</surname><given-names>OH</given-names></name><name><surname>Riis</surname><given-names>LB</given-names></name><etal/></person-group><article-title>TNF-&#x003b1;-induced down-regulation of CDX2 suppresses MEP1A expression in colitis</article-title><source>Biochim Biophys Acta</source><year>2012</year><volume>1822</volume><fpage>843</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2012.01.012</pub-id><pub-id pub-id-type="pmid">22326557</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Coskun M, Olsen AK, Holm TL, Kvist PH, Nielsen OH, Riis LB et al (2012) TNF-&#x003b1;-induced down-regulation of CDX2 suppresses MEP1A expression in colitis. Biochim Biophys Acta 1822:843&#x02013;51. 10.1016/j.bbadis.2012.01.012<pub-id pub-id-type="pmid">22326557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Henn</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Herbst</surname><given-names>C</given-names></name><name><surname>Hartman</surname><given-names>DJ</given-names></name><name><surname>Pai</surname><given-names>RK</given-names></name></person-group><article-title>Loss of SATB2 expression is a biomarker of inflammatory bowel disease-associated colorectal dysplasia and adenocarcinoma</article-title><source>Am J Surg Pathol</source><year>2019</year><volume>43</volume><fpage>1314</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001330</pub-id><pub-id pub-id-type="pmid">31318711</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ma C, Henn P, Miller C, Herbst C, Hartman DJ, Pai RK (2019) Loss of SATB2 expression is a biomarker of inflammatory bowel disease-associated colorectal dysplasia and adenocarcinoma. Am J Surg Pathol 43:1314&#x02013;22. 10.1097/PAS.0000000000001330<pub-id pub-id-type="pmid">31318711</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Elomaa</surname><given-names>H</given-names></name><name><surname>Ahtiainen</surname><given-names>M</given-names></name><name><surname>V&#x000e4;yrynen</surname><given-names>SA</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Friman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer</article-title><source>Br J Cancer</source><year>2022</year><volume>127</volume><fpage>514</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01822-6</pub-id><pub-id pub-id-type="pmid">35449453</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Elomaa H, Ahtiainen M, V&#x000e4;yrynen SA, Ogino S, Nowak JA, Friman M et al (2022) Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer. Br J Cancer 127:514&#x02013;23. 10.1038/s41416-022-01822-6<pub-id pub-id-type="pmid">35449453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Kastinen</surname><given-names>M</given-names></name><name><surname>Sirni&#x000f6;</surname><given-names>P</given-names></name><name><surname>Elomaa</surname><given-names>H</given-names></name><name><surname>&#x000c4;ij&#x000e4;l&#x000e4;</surname><given-names>VK</given-names></name><name><surname>Karjalainen</surname><given-names>H</given-names></name><name><surname>Tapiainen</surname><given-names>VV</given-names></name><etal/></person-group><article-title>Establishing criteria for tumor necrosis as prognostic indicator in colorectal cancer</article-title><source>Am J Surg Pathol</source><year>2024</year><volume>48</volume><fpage>1284</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000002286</pub-id><pub-id pub-id-type="pmid">39004843</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kastinen M, Sirni&#x000f6; P, Elomaa H, &#x000c4;ij&#x000e4;l&#x000e4; VK, Karjalainen H, Tapiainen VV et al (2024) Establishing criteria for tumor necrosis as prognostic indicator in colorectal cancer. Am J Surg Pathol 48:1284&#x02013;92. 10.1097/PAS.0000000000002286<pub-id pub-id-type="pmid">39004843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Elomaa</surname><given-names>H</given-names></name><name><surname>Ahtiainen</surname><given-names>M</given-names></name><name><surname>V&#x000e4;yrynen</surname><given-names>SA</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Lau</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer</article-title><source>Br J Cancer</source><year>2023</year><volume>128</volume><fpage>2104</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02238-6</pub-id><pub-id pub-id-type="pmid">37002343</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Elomaa H, Ahtiainen M, V&#x000e4;yrynen SA, Ogino S, Nowak JA, Lau MC et al (2023) Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer. Br J Cancer 128:2104&#x02013;15. 10.1038/s41416-023-02238-6<pub-id pub-id-type="pmid">37002343</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Elomaa</surname><given-names>H</given-names></name><name><surname>H&#x000e4;rk&#x000f6;nen</surname><given-names>J</given-names></name><name><surname>V&#x000e4;yrynen</surname><given-names>SA</given-names></name><name><surname>Ahtiainen</surname><given-names>M</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Quantitative multiplexed analysis of indoleamine 2,3-dioxygenase (IDO) and arginase-1 (ARG1) expression and myeloid cell infiltration in colorectal cancer</article-title><source>Mod Pathol</source><year>2024</year><volume>37</volume><fpage>100450</fpage><pub-id pub-id-type="doi">10.1016/J.MODPAT.2024.100450</pub-id><pub-id pub-id-type="pmid">38369188</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Elomaa H, H&#x000e4;rk&#x000f6;nen J, V&#x000e4;yrynen SA, Ahtiainen M, Ogino S, Nowak JA et al (2024) Quantitative multiplexed analysis of indoleamine 2,3-dioxygenase (IDO) and arginase-1 (ARG1) expression and myeloid cell infiltration in colorectal cancer. Mod Pathol 37:100450. 10.1016/J.MODPAT.2024.100450<pub-id pub-id-type="pmid">38369188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Bankhead</surname><given-names>P</given-names></name><name><surname>Loughrey</surname><given-names>MB</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>JA</given-names></name><name><surname>Dombrowski</surname><given-names>Y</given-names></name><name><surname>McArt</surname><given-names>DG</given-names></name><name><surname>Dunne</surname><given-names>PD</given-names></name><etal/></person-group><article-title>QuPath: open source software for digital pathology image analysis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>16878</fpage><pub-id pub-id-type="doi">10.1038/S41598-017-17204-5</pub-id><pub-id pub-id-type="pmid">29203879</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Bankhead P, Loughrey MB, Fern&#x000e1;ndez JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. 10.1038/S41598-017-17204-5<pub-id pub-id-type="pmid">29203879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><fpage>2498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498&#x02013;504. 10.1101/gr.1239303<pub-id pub-id-type="pmid">14597658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Chewchuk</surname><given-names>S</given-names></name><name><surname>Jahan</surname><given-names>S</given-names></name><name><surname>Lohnes</surname><given-names>D</given-names></name></person-group><article-title>Cdx2 regulates immune cell infiltration in the intestine</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>15841</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-95412-w</pub-id><pub-id pub-id-type="pmid">34349205</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Chewchuk S, Jahan S, Lohnes D (2021) Cdx2 regulates immune cell infiltration in the intestine. Sci Rep 11:15841. 10.1038/s41598-021-95412-w<pub-id pub-id-type="pmid">34349205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>Goerdt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Macrophage activation and polarization: nomenclature and experimental guidelines</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/J.IMMUNI.2014.06.008</pub-id><pub-id pub-id-type="pmid">25035950</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14&#x02013;20. 10.1016/J.IMMUNI.2014.06.008<pub-id pub-id-type="pmid">25035950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Slik</surname><given-names>K</given-names></name><name><surname>Turkki</surname><given-names>R</given-names></name><name><surname>Carp&#x000e9;n</surname><given-names>O</given-names></name><name><surname>Kurki</surname><given-names>S</given-names></name><name><surname>Korkeila</surname><given-names>E</given-names></name><name><surname>Sundstr&#x000f6;m</surname><given-names>J</given-names></name><etal/></person-group><article-title>CDX2 loss with microsatellite stable phenotype predicts poor clinical outcome in stage II colorectal carcinoma</article-title><source>Am J Surg Pathol</source><year>2019</year><volume>43</volume><fpage>1473</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001356</pub-id><pub-id pub-id-type="pmid">31490234</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Slik K, Turkki R, Carp&#x000e9;n O, Kurki S, Korkeila E, Sundstr&#x000f6;m J et al (2019) CDX2 loss with microsatellite stable phenotype predicts poor clinical outcome in stage II colorectal carcinoma. Am J Surg Pathol 43:1473&#x02013;82. 10.1097/PAS.0000000000001356<pub-id pub-id-type="pmid">31490234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Olevian</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Herbst</surname><given-names>C</given-names></name><name><surname>Jayachandran</surname><given-names>P</given-names></name><name><surname>Kozak</surname><given-names>MM</given-names></name><etal/></person-group><article-title>SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer</article-title><source>Mod Pathol</source><year>2019</year><volume>32</volume><fpage>1217</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41379-019-0265-1</pub-id><pub-id pub-id-type="pmid">30962505</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM et al (2019) SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Mod Pathol 32:1217&#x02013;31. 10.1038/s41379-019-0265-1<pub-id pub-id-type="pmid">30962505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Shima</surname><given-names>K</given-names></name><name><surname>Freed</surname><given-names>E</given-names></name><name><surname>Irahara</surname><given-names>N</given-names></name><name><surname>Philips</surname><given-names>J</given-names></name><etal/></person-group><article-title>Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>1665</fpage><lpage>4673</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0401</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J et al (2009) Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 15:1665&#x02212;4673. 10.1158/1078-0432.CCR-09-0401</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Cecchini</surname><given-names>MJ</given-names></name><name><surname>Walsh</surname><given-names>JC</given-names></name><name><surname>Parfitt</surname><given-names>J</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Correa</surname><given-names>RJ</given-names></name><name><surname>MacKenzie</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer</article-title><source>Hum Pathol</source><year>2019</year><volume>90</volume><fpage>70</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/J.HUMPATH.2019.05.005</pub-id><pub-id pub-id-type="pmid">31121192</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Cecchini MJ, Walsh JC, Parfitt J, Chakrabarti S, Correa RJ, MacKenzie MJ et al (2019) CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer. Hum Pathol 90:70&#x02013;9. 10.1016/J.HUMPATH.2019.05.005<pub-id pub-id-type="pmid">31121192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J-A</given-names></name><name><surname>Park</surname><given-names>HE</given-names></name><name><surname>Jin</surname><given-names>H-Y</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>N-Y</given-names></name><name><surname>Bae</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers</article-title><source>Ann Diagn Pathol</source><year>2024</year><volume>71</volume><fpage>152289</fpage><pub-id pub-id-type="doi">10.1016/j.anndiagpath.2024.152289</pub-id><pub-id pub-id-type="pmid">38555678</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Lee J-A, Park HE, Jin H-Y, Jin L, Cho N-Y, Bae JM et al (2024) Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers. Ann Diagn Pathol 71:152289. 10.1016/j.anndiagpath.2024.152289<pub-id pub-id-type="pmid">38555678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Hestetun</surname><given-names>KE</given-names></name><name><surname>Aaseb&#x000f8;</surname><given-names>K</given-names></name><name><surname>Rosenlund</surname><given-names>NB</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>Y</given-names></name><name><surname>Dahl</surname><given-names>O</given-names></name><name><surname>Myklebust</surname><given-names>MP</given-names></name></person-group><article-title>Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II&#x02013;III colon cancer</article-title><source>Mod Pathol</source><year>2020</year><volume>34</volume><fpage>161</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/s41379-020-0634-9</pub-id><pub-id pub-id-type="pmid">32737450</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hestetun KE, Aaseb&#x000f8; K, Rosenlund NB, M&#x000fc;ller Y, Dahl O, Myklebust MP (2020) Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II&#x02013;III colon cancer. Mod Pathol 34:161&#x02013;70. 10.1038/s41379-020-0634-9<pub-id pub-id-type="pmid">32737450</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>C&#x000ed;gerov&#x000e1;</surname><given-names>V</given-names></name><name><surname>Adamkov</surname><given-names>M</given-names></name><name><surname>Draho&#x00161;ov&#x000e1;</surname><given-names>S</given-names></name><name><surname>Grend&#x000e1;r</surname><given-names>M</given-names></name></person-group><article-title>Immunohistochemical expression and significance of SATB2 protein in colorectal cancer</article-title><source>Ann Diagn Pathol</source><year>2021</year><volume>52</volume><fpage>151731</fpage><pub-id pub-id-type="doi">10.1016/j.anndiagpath.2021.151731</pub-id><pub-id pub-id-type="pmid">33894556</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">C&#x000ed;gerov&#x000e1; V, Adamkov M, Draho&#x00161;ov&#x000e1; S, Grend&#x000e1;r M (2021) Immunohistochemical expression and significance of SATB2 protein in colorectal cancer. Ann Diagn Pathol 52:151731. 10.1016/j.anndiagpath.2021.151731<pub-id pub-id-type="pmid">33894556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Graule</surname><given-names>J</given-names></name><name><surname>Uth</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>E</given-names></name><name><surname>Centeno</surname><given-names>I</given-names></name><name><surname>Galv&#x000e1;n</surname><given-names>JA</given-names></name><name><surname>Eichmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway</article-title><source>Clin Epigenetics</source><year>2018</year><volume>10</volume><fpage>120</fpage><pub-id pub-id-type="doi">10.1186/S13148-018-0548-2</pub-id><pub-id pub-id-type="pmid">30257705</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Graule J, Uth K, Fischer E, Centeno I, Galv&#x000e1;n JA, Eichmann M et al (2018) CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics 10:120. 10.1186/S13148-018-0548-2<pub-id pub-id-type="pmid">30257705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>H</given-names></name><name><surname>Koelzer</surname><given-names>VH</given-names></name><name><surname>Lukesch</surname><given-names>AC</given-names></name><name><surname>Mallaev</surname><given-names>M</given-names></name><name><surname>Inderbitzin</surname><given-names>D</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Loss of Cdx2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer</article-title><source>Front Oncol</source><year>2013</year><volume>3</volume><fpage>63999</fpage><pub-id pub-id-type="doi">10.3389/FONC.2013.00265/BIBTEX</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Dawson H, Koelzer VH, Lukesch AC, Mallaev M, Inderbitzin D, Lugli A et al (2013) Loss of Cdx2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer. Front Oncol 3:63999. 10.3389/FONC.2013.00265/BIBTEX</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Elnady</surname><given-names>MS</given-names></name><name><surname>Eltatawy</surname><given-names>FA</given-names></name><name><surname>Nosseir</surname><given-names>AG</given-names></name><name><surname>Zamzam</surname><given-names>YA</given-names></name><name><surname>El-Guindy</surname><given-names>DM</given-names></name></person-group><article-title>Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study</article-title><source>Ecancermedicalscience</source><year>2022</year><volume>16</volume><fpage>1491</fpage><pub-id pub-id-type="doi">10.3332/ECANCER.2022.1491</pub-id><pub-id pub-id-type="pmid">36819801</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Elnady MS, Eltatawy FA, Nosseir AG, Zamzam YA, El-Guindy DM (2022) Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study. Ecancermedicalscience 16:1491. 10.3332/ECANCER.2022.1491<pub-id pub-id-type="pmid">36819801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Lagorce-Pages</surname><given-names>C</given-names></name><etal/></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id><pub-id pub-id-type="pmid">17008531</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960&#x02013;1964. 10.1126/science.1129139<pub-id pub-id-type="pmid">17008531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2368</fpage><pub-id pub-id-type="doi">10.3389/FIMMU.2019.02368</pub-id><pub-id pub-id-type="pmid">31681276</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K et al (2019) Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol 10:2368.&#x000a0;10.3389/FIMMU.2019.02368<pub-id pub-id-type="pmid">31681276</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>